公开(公告)号：WO2004018512A3

公开(公告)日：2004-07-01

申请号：PCT/EP0309356

申请日：2003-08-22

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  KERB REINHOLD ,  KOEPSELL HERMANN ,  BRINKMANN ULRICH

Inventor： KERB REINHOLD ,  KOEPSELL HERMANN ,  BRINKMANN ULRICH

IPC: A01K67/027 ,  A61K38/00 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C07K16/18 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/53

CPC classification number: C07K14/4702 ,  A01K2217/05 ,  A61K38/00 ,  C12Q1/6883

Abstract: The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

Abstract translation: 本发明涉及多态性OCT1多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体以及用本发明的多核苷酸或基因进行基因工程改造的宿主细胞。 此外，本发明涉及产生分子变体多肽或其片段的方法，产生能表达分子变异多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段， 方法或由本发明的方法产生的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人类动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。 另外，本发明涉及生产药物组合物的方法和诊断疾病的方法。 此外，本发明涉及检测本发明多核苷酸的方法。 此外，本发明包含诊断和药物组合物。 甚至更多地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。 最后，本发明涉及一种诊断试剂盒。

公开(公告)号：WO2004018512A2

公开(公告)日：2004-03-04

申请号：PCT/EP2003/009356

申请日：2003-08-22

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  KERB, Reinhold ,  KOEPSELL, Hermann ,  BRINKMANN, Ulrich

Inventor： KERB, Reinhold ,  KOEPSELL, Hermann ,  BRINKMANN, Ulrich

IPC: C07K14/47

CPC classification number: C07K14/4702 ,  A01K2217/05 ,  A61K38/00 ,  C12Q1/6883

Abstract: The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

Abstract translation: 本发明涉及多晶型OCT1多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。 此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段，或可由 方法或由本发明方法生产的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。 此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。 此外，本发明涉及本发明的多核苷酸的检测方法。 此外，本发明包括诊断和药物组合物。 更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。 最后，本发明涉及诊断试剂盒。

公开(公告)号：WO03097873A2

公开(公告)日：2003-11-27

申请号：PCT/EP0305120

申请日：2003-05-15

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  BROCKMOELLER HEINZ JUERGEN

Inventor： BROCKMOELLER HEINZ JUERGEN

IPC: C07K14/72 ,  C12N1/19 ,  C12N1/21 ,  C12Q1/68 ,  A01K67/027 ,  A61K48/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/63 ,  G01N33/50 ,  G01N33/53

CPC classification number: C07K14/72 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention relates to a polymorphic 5-Hydroxytryptamine (5-HT) receptor type 3B (HTR3B) polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide of the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

Abstract translation: 本发明涉及多晶型5-羟色胺（5-HT）受体3B型（HTR3B）多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。 此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法及其由本发明基因的多核苷酸编码的多肽或其片段的方法， 方法或由本发明方法生产的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，识别和获得前体药物或抑制剂的方法也包括在本发明中。 此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。 此外，本发明涉及本发明的多核苷酸的检测方法。 此外，本发明包括诊断和药物组合物。 更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。 最后，本发明涉及诊断试剂盒。

公开(公告)号：WO2003066892A1

公开(公告)日：2003-08-14

申请号：PCT/EP2003/001090

申请日：2003-02-04

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  SCHWAB, Matthias ,  SCHÄFFELER, Elke

Inventor： SCHWAB, Matthias ,  SCHÄFFELER, Elke

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  G01N2333/91011 ,  G01N2500/00

Abstract: The present invention relates to a polymorphic TPMT polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprise by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention for the preparation of pharmaceutical or diagnostic compositions. Finally, the invention relates to a diagnostic kit.

Abstract translation: 本发明涉及多形态TPMT多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。 此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段，或可由 方法或由本发明方法生产的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。 此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。 此外，本发明涉及本发明的多核苷酸的检测方法。 此外，本发明包括诊断和药物组合物。 更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体在制备药物或诊断组合物中的用途。 最后，本发明涉及诊断试剂盒。

公开(公告)号：WO2003013537A2

公开(公告)日：2003-02-20

申请号：PCT/EP2002/008218

申请日：2002-07-23

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH, Günther ,  KERB, Reinhold

Inventor： HEINRICH, Günther ,  KERB, Reinhold

IPC: A61K31/4745

CPC classification number: A61K31/4741 ,  A61K31/4745

Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a first, a second, a third, and/or a fourth variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a first, a second, a third and/or a fourth variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

Abstract translation: 本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途， 第一，第二，第三和/或第四变体等位基因，其包含根据本发明的多核苷酸。 优选地，与相应的野生型等位基因相比，所述多核苷酸所包含的核苷酸缺失，添加和/或取代导致第一，第二，第三和/或第四变体等位基因的改变的表达或多肽的改变的活性 由相应野生型等位基因编码的多肽与变体等位基因编码。 最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

公开(公告)号：WO2003013535A3

公开(公告)日：2003-02-20

申请号：PCT/EP2002/008220

申请日：2002-07-23

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH, Günther ,  KERB, Reinhold

Inventor： HEINRICH, Günther ,  KERB, Reinhold

IPC: A61K31/4745

Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

公开(公告)号：WO2003013533A3

公开(公告)日：2003-02-20

申请号：PCT/EP2002/008200

申请日：2002-07-23

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH, Günther ,  KERB, Reinhold

Inventor： HEINRICH, Günther ,  KERB, Reinhold

IPC: A61K31/4745

Abstract: The present invention relates to the use of irinotecan or derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

公开(公告)号：WO2001059152A3

公开(公告)日：2001-08-16

申请号：PCT/EP2001/001456

申请日：2001-02-09

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  ZANGER, Ulrich, M. ,  LANG, Thomas

Inventor： ZANGER, Ulrich, M. ,  LANG, Thomas

IPC: C12Q1/68

Abstract: Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expressionand/or function of the CYP2B6 genes. In particular, polynucleotides of molecular variant CYP2B6 genes which, for example, are associated with insufficient metabolization and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP2B6 proteins are described. In addition, variant CYP2B6 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP2B6 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP2B6 gene product are described as well.

公开(公告)号：WO03013536A9

公开(公告)日：2004-04-29

申请号：PCT/EP0208217

申请日：2002-07-23

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH GUENTHER ,  KERB REINHOLD

Inventor： HEINRICH GUENTHER ,  KERB REINHOLD

IPC: C12N15/09 ,  A61K31/235 ,  A61K31/277 ,  A61K31/341 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/409 ,  A61K31/4152 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/49 ,  A61K31/496 ,  A61K31/519 ,  A61K31/565 ,  A61K31/566 ,  A61K31/575 ,  A61K38/00 ,  A61K45/00 ,  A61P1/00 ,  A61P1/18 ,  A61P11/00 ,  A61P15/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07D491/052 ,  C07D491/22 ,  C12Q1/68

CPC classification number: A61K31/4741 ,  A61K31/4745

Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a varient allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in a altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

Abstract translation: 本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途， 包含根据本发明的多核苷酸的变体等位基因。 优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由 相应的野生型等位基因。 最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

公开(公告)号：WO2002099099A3

公开(公告)日：2002-12-12

申请号：PCT/EP2002/006000

申请日：2002-05-31

Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  PENGER, Anja ,  SPRENGER, Reimund ,  BRINKMANN, Ulrich

Inventor： PENGER, Anja ,  SPRENGER, Reimund ,  BRINKMANN, Ulrich

IPC: C12N9/02

Abstract: The present invention relates to a polymorphic CYP2C8-polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a prodrug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.